Avatrombopag

Drug Profile

Avatrombopag

Alternative Names: AKR-501; AKR-501 monomaleate; AVA; Avatrombopag maleate; E-5501; YM-477

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura; Thrombocytopenia

Most Recent Events

  • 06 Jan 2017 Dova Pharmaceuticals completes a phase III trial for Thrombocytopenia in USA, Canada, Japan, Australia, Argentina, Brazil, China, Mexico, Israel, France, Italy, the Czech Republic, Belgium, Germany, Spain, Romania and Russia
  • 06 Jan 2017 Dova Pharmaceuticals completes a phase III trial for Thrombocytopenia in USA, Canada, United Kingdom, Italy, Argentina, Australia, Austria, Hungary, Belgium, Brazil, Chile, China, France, Germany, Spain, Portugal, Poland, South Korea, Taiwan and Thailand
  • 01 Sep 2016 Eisai completes a phase I drug-drug interaction trial in Healthy volunteers in USA (PO) (NCT02809768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top